Yatai group cooperates with wilkell pharmaceutical to research new drugs and imitation projects such as Viagra and vcp-2

After years of development, the pharmaceutical industry of Yatai group now has a pharmaceutical R & D center, three manufacturing enterprises and a pharmaceutical chain retail enterprise, forming a complete industrial chain integrating R & D, production and sales Vecargrel is a kind of new chemical medicine, which can inhibit platelet aggregation after two steps of metabolism activation in human body It is a kind of platelet aggregation inhibitor for patients with acute coronary syndrome If the cooperation of this project is successful, it will further enhance the overall strength and profitability of the company's pharmaceutical industry Jiangsu Weikeli Pharmaceutical Technology Co., Ltd was established on August 31, 2010 with a registered capital of 13.5 million yuan The main research projects of the company are new drugs, generic drugs and chemicals such as vicargyle and vcp-2 Vecargrel is a new drug of chemotherapeutics, which is used to inhibit platelet aggregation in patients with acute coronary syndrome The project has applied for 9 domestic patents and 4 international patents, of which the patent for the compound and synthetic process of vicargyle has been authorized by China The international patent for vicargyle was disclosed to the United States, the European Union, Japan, South Korea and India on August 2, 2012, and obtained the United States patent on July 8, 2014 In April 2014, the application for new drug of vicargrel and its preparation vicargrel tablets was submitted to the State Food and Drug Administration and passed the on-site assessment Yatai group already has the idea of M & A of Jiama pharmaceutical industry At the recent shareholders' meeting of Yatai group, the company's plan for non-public issuance of shares was approved The company plans to raise no more than 2447.1 million yuan at a price of 3.47 yuan per share, all of which will be used to repay bank loans and supplement working capital It is reported that the company will make breakthrough progress in three aspects: prominent main business, improvement of financial structure and strategic transformation after the completion of this fixed increase In the field of strategic transformation, relevant personnel of the company said that the big health industry with medicine as the core is the future development focus According to media reports, the company's management personnel once said that it will not be excluded from the pharmaceutical chain, In order to achieve faster development, the heavy drug industry adopts the leapfrog acquisition The company is mainly familiar with anti-tumor drugs, biological products, traditional Chinese medicine and health care products, as well as chain retail network In the selection of M & A targets, the focus is on the enterprises that are competitive in the subdivision field or have complementary advantages with the company's sales network